KVD900 300 mg
Sponsors
KalVista Pharmaceuticals, Ltd.
Conditions
Hereditary Angioedema
Phase 3
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
CompletedNCT05259917
Start: 2022-02-22End: 2023-12-31Updated: 2025-05-02
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
CompletedNCT05505916
Start: 2022-10-24End: 2026-05-27Updated: 2026-06-05
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
CompletedNCT06467084
Start: 2024-08-01End: 2026-01-15Updated: 2026-08-05